PMID- 20220766
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20201215
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
VI  - 130
IP  - 6
DP  - 2010 Jun
TI  - Characterization of circulating dendritic cells in melanoma: role of CCR6 in 
      plasmacytoid dendritic cell recruitment to the tumor.
PG  - 1646-56
LID - 10.1038/jid.2010.24 [doi]
AB  - Dendritic cells (DCs) are central cells in the development of antitumor immune 
      responses, but the number and function of these cells can be altered in various 
      cancers. Whether these cells are affected during the development of melanoma is 
      not known. We investigated the presence, phenotype, and functionality of 
      circulating myeloid DCs (MDCs) and plasmacytoid DCs (PDCs) in newly diagnosed 
      melanoma patients, compared to controls. The frequencies of PDCs and MDCs were 
      equivalent in melanoma patients as compared with normal subjects. Both 
      circulating DC subsets were immature, but on ex vivo stimulation with R848 they 
      efficiently upregulated their expression of costimulatory molecules. We found 
      that circulating DCs from melanoma patients and controls displayed similar 
      pattern of expression of the chemokine receptors CXCR3, CXCR4, CCR7, and CCR10. 
      Strikingly, PDCs from melanoma patients expressed higher levels of CCR6 than 
      control PDCs, and were able to migrate toward CCL20. Further data showed that 
      CCR6-expressing PDCs were present in melanoma primary lesions, and that CCL20 was 
      produced in melanoma tumors. These results suggest that PDCs and MDCs are 
      functional in melanoma patients at the time of diagnosis, and that CCL20 may 
      participate to their recruitment from the blood to the tumor.
FAU - Charles, Julie
AU  - Charles J
AD  - INSERM U823, Centre de Recherche Albert Bonniot, Immunobiologie et Immunotherapie 
      des Cancers, Universite Joseph Fourier, R&D Laboratory, EFS Rhones-Alpes, 29 
      Avenue Maquis du Gresivaudan, La Tronche, France.
FAU - Di Domizio, Jeremy
AU  - Di Domizio J
FAU - Salameire, Dimitri
AU  - Salameire D
FAU - Bendriss-Vermare, Nathalie
AU  - Bendriss-Vermare N
FAU - Aspord, Caroline
AU  - Aspord C
FAU - Muhammad, Ramzan
AU  - Muhammad R
FAU - Lefebvre, Christine
AU  - Lefebvre C
FAU - Plumas, Joel
AU  - Plumas J
FAU - Leccia, Marie-Therese
AU  - Leccia MT
FAU - Chaperot, Laurence
AU  - Chaperot L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100311
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (CCR10 protein, human)
RN  - 0 (CCR6 protein, human)
RN  - 0 (CCR7 protein, human)
RN  - 0 (CXCR3 protein, human)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (Chemokine CCL20)
RN  - 0 (Receptors, CCR10)
RN  - 0 (Receptors, CCR6)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Receptors, CXCR3)
RN  - 0 (Receptors, CXCR4)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Cell Movement/physiology
MH  - Chemokine CCL20/physiology
MH  - Dendritic Cells/*pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Melanoma/*pathology/physiopathology
MH  - Middle Aged
MH  - Receptors, CCR10/physiology
MH  - Receptors, CCR6/*physiology
MH  - Receptors, CCR7/physiology
MH  - Receptors, CXCR3/physiology
MH  - Receptors, CXCR4/physiology
MH  - Skin Neoplasms/*pathology/physiopathology
EDAT- 2010/03/12 06:00
MHDA- 2010/06/16 06:00
CRDT- 2010/03/12 06:00
PHST- 2010/03/12 06:00 [entrez]
PHST- 2010/03/12 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
AID - S0022-202X(15)34865-X [pii]
AID - 10.1038/jid.2010.24 [doi]
PST - ppublish
SO  - J Invest Dermatol. 2010 Jun;130(6):1646-56. doi: 10.1038/jid.2010.24. Epub 2010 
      Mar 11.